Literature DB >> 18443311

Guillain-Barré syndrome: incidence and mortality rates in US hospitals.

Amer Alshekhlee1, Zulfiqar Hussain, Badr Sultan, Bashar Katirji.   

Abstract

OBJECTIVE: To determine the incidence, in-hospital mortality, and predictors of death in Guillain-Barré syndrome (GBS) in a large US cohort.
METHODS: Our cohort was identified from the Nationwide Inpatient Sample database, 2000 through 2004. We excluded patients younger than 18 years and those who presented with rapidly paralyzing conditions due to other causes. GBS patients who were transferred between hospitals were counted once. The incidence rate adjusted for 20% of the US census reported by the Census Bureau. A logistic regression model was used to identify predictors of death.
RESULTS: After data cleansing, 4,954 patients were identified with a primary diagnosis of GBS. The adjusted incidence rate varied between 1.65 and 1.79 per 100,000 during the years included in this study. The in-hospital mortality rate was 2.58% (128/4,954) and did not change significantly over the study period. Eleven percent had variable pulmonary complications, and 9.1% received endotracheal intubation, which was a predictor of mortality (adjusted odds ratio 5.09, 95% CI 3.21-8.05). Other predictors of mortality included older age, composite comorbidity index, cardiac complications, and sepsis.
CONCLUSION: The mortality rate in Guillain-Barré syndrome is low, and predictors of death are similar to those predicting poor disability outcome. The disease incidence was stable over the 5 years included in this study.

Entities:  

Mesh:

Year:  2008        PMID: 18443311     DOI: 10.1212/01.wnl.0000310983.38724.d4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  60 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome.

Authors:  F Khan; J F Pallant; L Ng; A Bhasker
Journal:  J Neurol       Date:  2010-07-13       Impact factor: 4.849

3.  Heart rate variability and baroreflex sensitivity abnormalities in Guillain-Barré syndrome: a pilot study.

Authors:  Cheng-Yin Tan; Nortina Shahrizaila; Kee-Ying Yeoh; Khean-Jin Goh; Maw-Pin Tan
Journal:  Clin Auton Res       Date:  2018-04-13       Impact factor: 4.435

4.  Incidence and prevalence of CIDP and the association of diabetes mellitus.

Authors:  R S Laughlin; P J Dyck; L J Melton; C Leibson; J Ransom; P J B Dyck
Journal:  Neurology       Date:  2009-07-07       Impact factor: 9.910

Review 5.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

Review 6.  Guillain-barré syndrome: modern theories of etiology.

Authors:  Todd A Hardy; Stefan Blum; Pamela A McCombe; Stephen W Reddel
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

Review 7.  Immunotherapy of Guillain-Barré syndrome.

Authors:  Shuang Liu; Chaoling Dong; Eroboghene Ekamereno Ubogu
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

8.  Pioglitazone, PPARγ agonist, attenuates experimental autoimmune neuritis.

Authors:  Hhoonisha Ramkalawan; Yu-Zhong Wang; Ameet Hurbungs; Yan-Fang Yang; Fa-Fa Tian; Wen-Bin Zhou; Jing Li; Huan Yang; Bo Xiao; Wei Zhang
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

Review 9.  Assessing the global threat from Zika virus.

Authors:  Justin Lessler; Lelia H Chaisson; Lauren M Kucirka; Qifang Bi; Kyra Grantz; Henrik Salje; Andrea C Carcelen; Cassandra T Ott; Jeanne S Sheffield; Neil M Ferguson; Derek A T Cummings; C Jessica E Metcalf; Isabel Rodriguez-Barraquer
Journal:  Science       Date:  2016-07-14       Impact factor: 47.728

10.  Silencing of miR155 promotes the production of inflammatory mediators in Guillain-Barré syndrome in vitro.

Authors:  Yu-Zhong Wang; Xun-Gang Feng; Qi-Guang Shi; Yan-Lei Hao; Yan Yang; Ai-Mei Zhang; Qing-Xia Kong
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.